Business context and reporting period
The supplied filing is Sunshine Heart, Inc.’s Form 10-Q for the quarter ended September 30, 2014—not a filing identified as Nuwellis, Inc. Sunshine Heart was developing the C-Pulse heart-assist system for heart failure. U.S. sales were limited to devices implanted under clinical-study arrangements; the system was not approved for U.S. commercial sale.
Financial results and position
Amounts are in thousands of U.S. dollars, except per-share data.
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Revenue | $59 | $59 | $118 | $59 |
| Operating expenses | $6,169 | $6,233 | $19,249 | $15,935 |
| Operating loss | $(6,110) | $(6,174) | $(19,131) | $(15,876) |
| Net loss | $(6,132) | $(6,035) | $(18,844) | $(14,654) |
| Basic and diluted loss per share | $(0.36) | $(0.47) | $(1.12) | $(1.29) |
| Operating cash used | — | — | $17,358 | $11,755 |
At September 30, 2014, cash and cash equivalents were $36.575 million, versus $54.136 million at December 31, 2013. Current assets were $37.197 million and current liabilities were $2.729 million. Total liabilities were $2.729 million; the balance sheet reported no debt. The filing does not report a gross margin, and the company expensed clinical-study product costs as research and development. Cash used in investing activities was $205,000 for the first nine months of 2014; financing provided $16,000, compared with $57.591 million in the 2013 period. Accumulated deficit was $119.856 million.
Material changes versus the prior comparable period
- Quarterly revenue was unchanged; nine-month revenue doubled to $118,000, reflecting two reimbursable device implants versus one in the 2013 period.
- Nine-month research and development expense rose 31.8% to $12.284 million, primarily due to personnel and clinical-research infrastructure for studies in North America and Europe. Quarterly R&D expense increased 1.6%.
- Nine-month selling, general and administrative expense rose 5.3% to $6.965 million, while quarterly expense fell 5.0%, mainly reflecting the timing and structure of stock-based compensation.
- Nine-month net loss increased to $18.844 million from $14.654 million. Loss per share improved, in part alongside a higher weighted-average share count; the filing does not attribute the change to improved operating performance.
- Operating cash use increased by $5.603 million year over year. Cash declined by $17.561 million from year-end 2013, while the comparable 2013 period included substantial equity financing.
Outlook, risks and unusual items
- Management expected R&D expense to remain above prior-year levels through 2014 and SG&A to reflect infrastructure investment and fluctuating share-based compensation. Revenue was expected to remain minimal until North American pivotal-study enrollment increased and European post-market-study reimbursement was established. No numerical earnings or revenue guidance was provided.
- The company disclosed substantial dependence on raising additional capital and on developing and commercializing its product; unsuccessful or untimely financing could jeopardize its ability to continue as a going concern. Management believed it could raise equity as required, but gave no assurance of success.
- The C-Pulse had FDA authorization for a U.S. pivotal study, with enrollment begun in Q3 2013; CE Mark approval had been obtained in July 2012, and a European post-market study was underway. Regulatory approval, clinical outcomes, reimbursement, commercialization, and financing remained key uncertainties.
- Australian R&D tax credits contributed a $265,000 benefit in the 2014 nine-month period. The company had not determined whether it would receive a refund for the tax period ended June 30, 2014; it expected future refunds, if any, to decline. The 2013 comparison included Australian and Minnesota credits.
- The company reported no material legal proceedings, no off-balance-sheet arrangements, and no material capital-expenditure commitments. Management concluded disclosure controls were effective at a reasonable-assurance level.
Important facts for investors to verify
- Confirm issuer identity: the supplied document names Sunshine Heart, Inc., not Nuwellis, Inc.
- Verify the filing period and issuer against the original SEC filing before relying on these figures.
- Track cash burn, available financing, and the company’s ability to fund operations; the filing does not provide a cash-runway estimate.
- Check progress and results of the U.S. pivotal and European post-market studies, as well as regulatory and reimbursement developments.
- Assess whether clinical-study revenue can grow into commercial revenue and whether rising R&D and infrastructure spending can be sustained.